Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T
Department of Laboratory Medicine, Clinical Pathology-Toxicology, Ospedale S Agostino-Estense, Modena, Italy.
UO Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria, Parma, Italy.
Pharmacogenomics J. 2016 Feb;16(1):18-29. doi: 10.1038/tpj.2015.28. Epub 2015 Apr 28.
Polymorphism of interleukin 28B gene represents a powerful outcome predictor for interferon-based regimens in hepatitis C virus infection. However, some studies report conflicting results. The predictive value of interleukin 28B genotype over the outcome interferon-α/ribavirin treatment was thoroughly evaluated and compared with virological predictors of response. Literature revision was performed on PubMed. Pooled odds ratios (ORs) were calculated by fixed- or random-effects models. Heterogeneity and publication bias were also assessed. Sixty-two eligible papers including 20 290 patients were retrieved. Both polymorphisms (rs12979860 and rs8099917) were strongly associated with response (OR=4.09 and 4.00, respectively), however, the association was weaker for subjects infected with viral genotypes 2 and 3 (OR=1.52 and 1.49, respectively). Compared with interleukin 28B genotype, the association with response was lower for baseline viremia (OR=2.15) and higher for rapid virological response (OR=13.86). These results provide a critical evaluation of interleukin 28B genotype as a pharmacogenetic predictor in hepatitis C patients.
白细胞介素28B基因多态性是丙型肝炎病毒感染中基于干扰素治疗方案疗效的有力预测指标。然而，一些研究报告了相互矛盾的结果。对白细胞介素28B基因型在α干扰素/利巴韦林治疗疗效方面的预测价值进行了全面评估，并与反应的病毒学预测指标进行了比较。在PubMed上进行了文献综述。采用固定效应或随机效应模型计算合并比值比（OR）。还评估了异质性和发表偏倚。检索到62篇符合条件的论文，共纳入20290例患者。两种多态性（rs12979860和rs8099917）均与治疗反应密切相关（OR分别为4.09和4.00），然而，对于感染病毒基因型2和3的患者，这种相关性较弱（OR分别为1.52和1.49）。与白细胞介素28B基因型相比，基线病毒血症与治疗反应的相关性较低（OR=2.15），而快速病毒学反应与治疗反应的相关性较高（OR=13.86）。这些结果为白细胞介素28B基因型作为丙型肝炎患者药物遗传学预测指标提供了重要评估。
